Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events

European Urology, Supplements

Volumn 7, Issue 10, 2008, Pages 667-674

  Witjes, J Alfred ^a   Palou, Joan ^b   Soloway, Mark ^c   Lamm, Donald ^d   Brausi, Maurizio ^e   Spermon, J Roan ^a   Persad, Raj ^f   Buckley, Roger ^g   Akaza, Hideyuki ^h   Colombel, Marc ⁱ   Böhle, Andreas ^j  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e AUSL Modena   (Italy)

^f BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

^g NORTH YORK GENERAL HOSPITAL   (Canada)

^h UNIVERSITY OF TSUKUBA   (Japan)

ⁱ UNIVERSITÉ LYON 1   (France)

^j HELIOS AGNES KARLL HOSPITAL   (Germany)

more..

Author keywords

Bladder calcifications; Contact dermatitis; Contracted bladder; Cystitis; Epididymo orchitis; Granulomatous prostatitis; Hematuria; Intravesical therapy associated adverse events; Myelosuppression; Systemic bacillus Calmette Gu rin reactions

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; BCG VACCINE; CIPROFLOXACIN; CORTICOSTEROID; DOXORUBICIN; EPIRUBICIN; ETHAMBUTOL; IMMUNOMODULATING AGENT; ISONIAZID; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; OXYBUTYNIN; PHENAZOPYRIDINE; PLACEBO; PROPANTHELINE BROMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STEROID;

ALLERGIC REACTION; ARTHRALGIA; BACTERIAL INFECTION; BLADDER CALCIFICATION; BLADDER CANCER; BLADDER CONTRACTION; BLADDER DISEASE; BLADDER IRRIGATION; BONE MARROW SUPPRESSION; CALCIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CATHETERIZATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTACT DERMATITIS; CONTRACTED BLADDER; CYSTECTOMY; CYSTITIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIDIDYMIS DISEASE; EPIDIDYMOORCHITIS; FEVER; GANGRENE; GRANULOMATOSIS; HAND WASHING; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEMATURIA; HEMODYNAMICS; HEPATOMEGALY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LIVER FUNCTION; LUNG DISEASE; MALAISE; MEDICAL EDUCATION; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; NONHUMAN; ORCHIECTOMY; PENIS DISEASE; PENIS GANGRENE; PERCUTANEOUS DRAINAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATITIS; RASH; REVIEW; SIDE EFFECT; SYSTEMIC DISEASE; TRANSURETHRAL RESECTION; TUBERCULOSIS; URETER OBSTRUCTION; URETER STENT; URINARY TRACT INFECTION; VACCINATION REACTION;

EID: 51349114054     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.08.001     Document Type: Review

References (28)

1. van der Meijden A.P.M., Sylvester R.J., Oosterlinck W., Hoeltl W., Bono A.V., and for the EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 44 (2003) 429-434
2. Saint F., Irani J., Patard J.J., et al. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 57 (2001) 883-888
3. Böhle A., Balck F., von Wietersheim J., and Jocham D. The quality of life during intravesical bacillus Calmette-Guérin therapy. J Urol 155 (1996) 1221-1226
4. Thrasher J.B., and Crawford E.D. Complications of intravesical chemotherapy. Urol Clin North Am 19 (1992) 529-539
5. van der Meijden A.P., Brausi M., Zambon V., Kirkels W., de Balincourt C., Sylvester R., and EORTC Genito-Urinary Group. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol 166 (2001) 476-481
6. Vegt P.D., van der Meijden A.P., Sylvester R., Brausi M., Höltl W., de Balincourt C., and EORTC Genito-Urinary Group. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guérin therapy in superficial bladder cancer? Interim results of cancer protocol 30911. J Urol 157 (1997) 1246-1249
7. Rischmann P., Desgrandchamps F., Malavaud B., and Chopin D.K. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37 Suppl 1 (2000) 33-36
8. Lundholm C., Norlén B.J., Ekman P., et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 156 (1996) 372-376
9. Nieder A.M., Sved P.D., Stein J.P., Skinner D.G., and Soloway M.S. Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette Guérin-induced bladder contractures. Urology 65 (2005) 909-912
10. Lamm D.L. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 19 (1992) 565-572
11. Steg A., Leleu C., Debre B., Boccon-Gibod L., and Sicard D. Systemic bacillus Calmette-Guérin infection: "BCGitis" in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol 16 (1989) 161-164
12. Terris M.K., Macy M., and Freiha F.S. Transrectal ultrasound appearance of prostatic granulomas secondary to bacillus Calmette-Guérin instillation. J Urol 158 (1997) 126-127
13. Falkensammer C., Gozzi C., Hager M., et al. Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guerin therapy for superficial bladder carcinoma. Urology 65 (2005) 175
14. Krege S., Giani G., Meyer R., Otto T., and Rübben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. Participating clinics. J Urol 156 (1996) 962-966
15. Durek C., Rüsch-Gerdes S., Jocham D., and Böhle A. Interference of modern antibacterials with bacillus Calmette-Guerin viability. J Urol 162 (1999) 1959-1962
16. Durek C., Rüsch-Gerdes S., Jocham D., and Böhle A. Sensitivity of BCG to modern antibiotics. Eur Urol Suppl 37 Suppl 1 (2003) 21-25
17. Koya M.P., Simon M.A., and Soloway M.S. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 175 (2006) 2004-2010
18. Kureshi F., Kalaaji A.N., Halvorson L., Pittelkow M.R., and Davis M.D. Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy. J Am Acad Dermatol 55 (2006) 328-331
19. Drago P.C., Badalament R.A., Lucas J., and Drago J.R. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer. J Urol 142 (1989) 1071-1072
20. Fiore A.A., Iorio B., Vennarecci G., et al. Papillary-like bladder calcifications following intravescical mitomycin C. A case report. Minerva Urol Nefrol 45 (1993) 171-173
21. Durek C., Jurczok A., Werner H., Jocham D., and Bohle A. Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model. J Urol 168 (2002) 826-831
22. Issell B.F., Prout G.R., Soloway M.S., et al. Mitomycin C intravesical therapy in non-invasive bladder cancer after failure of thiotepa. Cancer 53 (1984) 1025-1028
23. Zein T.A., Friedberg N., and Kim H. Bone marrow suppression after intravesical mitomycin C treatment. J Urol 136 (1986) 459-460
24. Martinez-Pineiro J.A., Flores N., Isorna S., et al., CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671-680
25. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., et al., CUETO (Club Urologico Espanol de Tratamiento Oncologico). Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247
26. Ojea A., Nogueira J.L., Solsona E., et al., Members of the CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
27. Colombel M., Saint F., Chopin D., Nicolas L., and Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176 (2006) 935-939
28. Buckley R, Rischmann P, Colombel M, et al. Prophylactic ofloxacin to improve tolerance of BCG instillations: two-year results of a prospective double-blind placebo-controlled study in patients with bladder cancer [abstract PD-11.12]. Poster presented at: 28th Congress of the Société Internationale d'Urologie (SIU); November 12-16, 2006; Cape Town, South Africa.